Company news

Allarity Therapeutics, Inc. news in 2022

Allarity Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date

November 30, 2022

Allarity Therapeutics Reports Third Quarter 2022 Financial Results

November 14, 2022

Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders

November 6, 2022

Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements

October 10, 2022

Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors

September 25, 2022

Allarity Therapeutics to Present at Ladenburg Thalmann Healthcare Conference

September 15, 2022

Allarity Therapeutics Announces Appointment of New Auditor

September 11, 2022

Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

August 25, 2022

Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies

August 1, 2022

Allarity Therapeutics Bolsters Its Board of Directors with Appointment of Prominent Clinical Researcher and Oncology Drug Developer, David A. Roth, M.D.

July 10, 2022

Allarity Therapeutics Announces Executive Leadership Transition

June 28, 2022

Allarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili, M.D.

June 14, 2022

Allarity Therapeutics Reports First Quarter 2022 Financial Results

May 26, 2022

Correction Notice to Press Release Announcing Financial Results For the Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

May 17, 2022

Allarity Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

May 15, 2022

Allarity Therapeutics Provides Update on Dovitinib Program

March 14, 2022

Allarity Therapeutics Receives Refusal to File Letters from U.S. FDA

February 17, 2022

Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib

January 2, 2022

Decks in 2022